Does anticholinergics drug burden relate to global neuro-disability outcome measures and length of hospital stay?

Brain Injury

Volumn 29, Issue 12, 2015, Pages 1426-1430

  Sakel, M ^a   Boukouvalas, A ^b   Buono, R ^c   Moten, M ^d   Mirza, F ^a   Chan, W Y ^e   Maidment, I ^b   Cross, J ^f   Smith, T O ^f   Myint, P K ^c   Fox, C ^f  

^a UNIVERSITY OF KENT   (United Kingdom)

^b ASTON UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^f UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

adverse event; Anticholingeric; function; length of stay; rehabilitation unit; spinal cord; traumatic brain injury

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; BRAIN INJURY; CLINICAL ASSESSMENT TOOL; DISABILITY; FEMALE; FUNCTIONAL ASSESSMENT MEASURE; FUNCTIONAL INDEPENDENCE MEASURE; HOSPITAL ADMISSION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; NORTHWICK PARK DEPENDENCY SCORE; OUTCOME ASSESSMENT; REHABILITATION CARE; REHABILITATION CENTER; REHABILITATION COMPLEXITY SCALE; RETROSPECTIVE STUDY; SPINAL CORD INJURY; BRAIN INJURIES; COMPARATIVE STUDY; CONVALESCENCE; DISABLED PERSON; HOSPITALIZATION; MIDDLE AGED; PATHOPHYSIOLOGY; SPINAL CORD INJURIES; TRENDS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BRAIN INJURIES; CHOLINERGIC ANTAGONISTS; DISABLED PERSONS; FEMALE; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RECOVERY OF FUNCTION; REHABILITATION CENTERS; RETROSPECTIVE STUDIES; SPINAL CORD INJURIES;

EID: 84947039309     PISSN: 02699052     EISSN: 1362301X     Source Type: Journal    
DOI: 10.3109/02699052.2015.1060358     Document Type: Article

References (17)

1. Ness J, Hoth A, Barnett M, Shorr R, Kaboli P. Anti-cholinergic medications in community-dwelling older veterans: Prevalence of anti-cholinergic symptoms, symptom burden and adverse drug events. American Journal of Geriatric Pharamacotherapy 2006;4: 42-51.
2. Gurwitz J, Field T, Harrold L. Incidence and preventability of adverse drug events amongst older persons in the ambulatory setting. Journal of the American Medical Association 2003;289:1107-1116.
3. Campbell N, Boustani M, Limbil T, Ott C, Fox C, Maidment I Schubert CC, Munger S, Fick D, Miller D, et al. The cognitive impact of anti-cholinergics: A clinical review. Clinical Interventions in Aging 2009;4:225-233.
4. Tannenbaum C, Paquette A, Hilmer S, Holroyd-Leduc J, Camahan R. A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs. Drugs & Aging 2012;29:639-658.
5. Fox C, Smith T, Maidment I, Chan WY, Bua N, Myint PK, Boustani M, Kwok CS, Glover M Koopmans I, et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: A systematic review. Age & Ageing 2014;43:604-615.
6. Jessen F, Kaduszkiewicz H, Daerr M, Bickel H, Pentzek M, Riedel-Heller S, Wagner M, Weyerer S, Wiese B, van den Bussche H, et al. Anticholinergic drug use and risk for dementia: Target for dementia prevention. European Archives of Psychiatry & Clinical Neurosciences 2010;260:S111-S115.
7. Ancelin ML, Artero S, Portet F, Dupuy AM, Touchon J, Ritchie K. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: Longitudinal cohort study. British Medical Journal 2006;332:455-459.
8. Carriere I, Fourrier-Reglat A, Dartigues JF, Rouaud O, Pasquier F, Ritchie K, Ancelin ML. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: The 3-city study. Archives of Internal Medicine 2009;169: 1317-1324.
9. Blane K. 2013, NHS Commissioning Board-Section B Part 1-Service Specifications-Specialised rehabilitation for patients with highly complex needs, 2014. Available online at: http://www.england. nhs.uk/wp-content/uploads/2014/04/d02-rehab-pat-highneeds-0414.pdf, accessed 18 September 2014.
10. Campbell NL, Maidment I, Fox C, Khan B, Boustani M. The 2012 Update to the Anticholinergic Cognitive Burden Scale. Journal of the American Geriatric Society 2013;61:S1-232.
11. Turner-Stokes L. UKROC-UK Rehabilitation Outcomes Collaborative, 2014. Available at: http://www.csi.kcl.ac.uk/ukroc, accessed 13 September 2014.
12. Fox C, Richardson K, Maidment I, Smithard D, Katona C, Boustani M, Savva GM, Coulton S, Matthews FE, Brayne C on behalf of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Anticholinergic medication use and cognitive impairment in the older population: The Medical Research Council Cognitive Function and Ageing Study. Journal of the American Medical Association 2010;59:1477-1483.
13. Wagg A, Dale M, Tretter R, Stowe B, Compion G. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: The SENIOR study. European Urology 2013;64:74-81.
14. Kidd CA, Musonda P, Soiza RL, Butchart C, Lunt CJ, Pai Y, Hameed Y, Fox GC, Potter JF, Myint PK. The relationship between total anticholinergic burden (ACB) and early in-patient hospital mortality and length of stay in the oldest old (90 years and over) admitted with an acute illness. Archives of Gerontology & Geriatrics 2014;59:155-161.
15. Medcalf P, Russell GK. Homeless healthcare: Raising the standards. Clinical Medicine 2014;14:349-353.
16. Horn SD, DeJong G, Deutscher D. Practice-based evidence research in rehabilitation: An alternative to randomized controlled trials and traditional observational studies. Archives of Physical Medicine & Rehabilitation 2012;93:S127-137.
17. Royal College of Physicians. Medical rehabilitation in 2011 and beyond. Report of a working party. London, England: Royal College of Physicians; 2010.